The molecular pathology of cancer.

Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12

Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev (2011) 2.31

A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16

Molecular biology of lung cancer: clinical implications. Clin Chest Med (2011) 1.47

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer (2011) 1.35

The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.32

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci U S A (2013) 1.25

Brain tumor microvesicles: insights into intercellular communication in the nervous system. Cell Mol Neurobiol (2011) 1.22

Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum Mol Genet (2014) 1.15

KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J Hum Genet (2011) 1.14

Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology (2012) 1.09

Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci (2011) 1.08

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med (2012) 1.07

A strategy for distinguishing optimal cancer subtypes. Int J Cancer (2010) 1.03

Cancer systems biology: embracing complexity to develop better anticancer therapeutic strategies. Oncogene (2014) 1.00

Active learning framework with iterative clustering for bioimage classification. Nat Commun (2012) 0.94

The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells. Oncogene (2012) 0.94

Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogenesis (2014) 0.93

Histological Stains: A Literature Review and Case Study. Glob J Health Sci (2015) 0.91

Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol (2016) 0.91

K-Ras mediated murine epidermal tumorigenesis is dependent upon and associated with elevated Rac1 activity. PLoS One (2011) 0.90

In situ biomarker discovery and label-free molecular histopathological diagnosis of lung cancer by ambient mass spectrometry imaging. Sci Rep (2015) 0.90

Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomed Rep (2013) 0.90

Lauriston S. Taylor Lecture on radiation protection and measurements: what makes particle radiation so effective? Health Phys (2012) 0.90

Incremental costs of prostate cancer trials: Are clinical trials really a burden on a public payer system? Can Urol Assoc J (2013) 0.89

Distinct involvement of the Gab1 and Grb2 adaptor proteins in signal transduction by the related receptor tyrosine kinases RON and MET. J Biol Chem (2011) 0.88

MicroRNA-206 functions as a tumor suppressor in colorectal cancer by targeting FMNL2. J Cancer Res Clin Oncol (2015) 0.87

Deregulation of cell signaling in cancer. FEBS Lett (2014) 0.87

A conceptual and methodological framework for investigating etiologic heterogeneity. Stat Med (2013) 0.86

Gene and drug matrix for personalized cancer therapy. Nat Rev Drug Discov (2010) 0.86

Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol (2014) 0.84

EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition. J Exp Clin Cancer Res (2014) 0.83

SP1-mediated microRNA-520d-5p suppresses tumor growth and metastasis in colorectal cancer by targeting CTHRC1. Am J Cancer Res (2015) 0.83

Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer. Chin J Cancer (2012) 0.82

Specific and sensitive hydrolysis probe-based real-time PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma. PLoS One (2012) 0.82

An emerging toolkit for targeted cancer therapies. Genome Res (2012) 0.81

Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism. J Carcinog (2011) 0.80

Host genetic background impacts modulation of the TLR4 pathway by RON in tissue-associated macrophages. Immunol Cell Biol (2013) 0.80

Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol (2010) 0.79

Challenges in identifying candidate amplification targets in human cancers: chromosome 8q21 as a case study. Genes Cancer (2012) 0.79

Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer. Cancer Med (2015) 0.79

An update on miRNAs as biological and clinical determinants in colorectal cancer: a bench-to-bedside approach. Future Oncol (2015) 0.79

In vivo molecular mapping of the tumor microenvironment in an azoxymethane-treated mouse model of colon carcinogenesis. Lasers Surg Med (2014) 0.78

Modelling gene expression profiles related to prostate tumor progression using binary states. Theor Biol Med Model (2013) 0.78

Instability of the octarepeat region of the human prion protein gene. PLoS One (2011) 0.78

In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. Oncogene (2016) 0.78

Vitamin D receptor Cdx-2 polymorphism and premenopausal breast cancer risk in southern Pakistani patients. PLoS One (2015) 0.78

microRNA -140-5p inhibits colorectal cancer invasion and metastasis by targeting ADAMTS5 and IGFBP5. Stem Cell Res Ther (2016) 0.78

Genomic investigation of etiologic heterogeneity: methodologic challenges. BMC Med Res Methodol (2014) 0.76

pRb controls estrogen receptor alpha protein stability and activity. Oncotarget (2013) 0.76

CDK5 functions as a tumor promoter in human colorectal cancer via modulating the ERK5-AP-1 axis. Cell Death Dis (2016) 0.75

A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers. Sci Rep (2016) 0.75

Stromal interaction molecule 1 (STIM1) regulates growth, cell cycle and apoptosis of human tongue squamous carcinoma cells. Biosci Rep (2017) 0.75

Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers. Cancer Inform (2016) 0.75

Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma. World J Hepatol (2016) 0.75

Genetics of Hyperparathyroidism, Including Parathyroid Cancer. Endocrinol Metab Clin North Am (2017) 0.75

An XIST-related small RNA regulates KRAS G-quadruplex formation beyond X-inactivation. Oncotarget (2016) 0.75

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS. Leukemia (2016) 0.75

Maintenance of glia in the optic lamina is mediated by EGFR signaling by photoreceptors in adult Drosophila. PLoS Genet (2015) 0.75

MicroRNA-613 targets FMNL2 and suppresses progression of colorectal cancer. Am J Transl Res (2016) 0.75

Molecular portraits of human breast tumours. Nature (2000) 94.14

Finding the missing heritability of complex diseases. Nature (2009) 67.95

Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35

The diploid genome sequence of an Asian individual. Nature (2008) 46.29

Sequencing technologies - the next generation. Nat Rev Genet (2009) 40.57

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13

The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09

Targeted capture and massively parallel sequencing of 12 human exomes. Nature (2009) 33.96

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23

K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75

A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27

The cancer genome. Nature (2009) 23.13

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96

The impact of next-generation sequencing technology on genetics. Trends Genet (2008) 21.07

Common genetic variation and human traits. N Engl J Med (2009) 21.03

A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39

A HapMap harvest of insights into the genetics of common disease. J Clin Invest (2008) 18.31

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature (2008) 18.21

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08

Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A (2008) 17.41

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med (2001) 16.65

Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58

Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17

A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10

Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63

Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43

Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34

Genetic mapping in human disease. Science (2008) 15.12

Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer (2007) 14.84

Use of electronic health records in U.S. hospitals. N Engl J Med (2009) 14.36

Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54

Lung cancer. N Engl J Med (2008) 13.49

Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer (2009) 12.92

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46

Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34

Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2007) 10.81

Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A (2008) 10.52

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12

Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet (2007) 9.88

Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64

Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science (2008) 9.25

Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23

Genomewide association studies--illuminating biologic pathways. N Engl J Med (2009) 8.83

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature (2009) 8.44

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43

A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39

Single-molecule sequencing of an individual human genome. Nat Biotechnol (2009) 8.35

A loss-of-function RNA interference screen for molecular targets in cancer. Nature (2006) 8.11

Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med (2006) 7.42

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature (2009) 7.37

Genetic risk prediction--are we there yet? N Engl J Med (2009) 7.30

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97

A highly annotated whole-genome sequence of a Korean individual. Nature (2009) 6.91

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res (2008) 6.91

Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science (2008) 6.52

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov (2009) 6.36

A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell (2009) 6.23

Molecular diagnosis of Burkitt's lymphoma. N Engl J Med (2006) 6.10

Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04

MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol (2009) 5.92

Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80

1000 Genomes project. Nat Biotechnol (2008) 5.73

Oncogene addiction. Cancer Res (2008) 5.66

The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling. Nat Genet (2009) 5.65

MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell (2008) 5.34

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res (2008) 5.18

The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer (2008) 5.07

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med (2009) 4.68

The cancer biomarker problem. Nature (2008) 4.64

Validating, augmenting and refining genome-wide association signals. Nat Rev Genet (2009) 4.56

Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet (2009) 4.47

Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol (2006) 4.35

Frequent inactivation of A20 in B-cell lymphomas. Nature (2009) 4.22

An agenda for personalized medicine. Nature (2009) 4.14

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol (2009) 4.14

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest (2007) 4.07

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36

The RB and p53 pathways in cancer. Cancer Cell (2002) 8.02

Chromosome aberrations in solid tumors. Nat Genet (2003) 7.01

Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev (2003) 4.89

Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell (2003) 4.32

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res (2005) 3.98

Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science (2006) 3.96

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14

Ras signaling and therapies. Adv Cancer Res (2009) 2.93

Therapeutic strategies for targeting ras proteins. Genes Cancer (2011) 2.45

Combinatorial patterns of somatic gene mutations in cancer. FASEB J (2008) 2.40

Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer (2004) 2.32

A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell (2005) 2.27

Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol (2004) 2.27

Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 2.23

PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation. Cancer Res (2008) 2.20

SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12

Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res (2004) 2.09

Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene (2005) 2.06

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05

A critical role for FBXW8 and MAPK in cyclin D1 degradation and cancer cell proliferation. PLoS One (2006) 2.05

Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell (2005) 1.96

Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene (2003) 1.93

Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Cancer Cell (2013) 1.89

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell (2013) 1.73

Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res (2003) 1.70

A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell (2006) 1.68

EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal (2009) 1.66

An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res (2004) 1.64

Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov (2012) 1.62

Tpr directly binds to Mad1 and Mad2 and is important for the Mad1-Mad2-mediated mitotic spindle checkpoint. Genes Dev (2008) 1.59

Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS One (2007) 1.56

A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia (2004) 1.54

Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene (2004) 1.52

Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res (2002) 1.50

Adenoviral proteins mimic nutrient/growth signals to activate the mTOR pathway for viral replication. EMBO J (2005) 1.47

Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol Cell (2008) 1.45

DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res (2008) 1.42

Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back. Am J Med Genet A (2010) 1.36

Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell (2010) 1.35

A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1. Genes Dev (2012) 1.33

p97/DAP5 is a ribosome-associated factor that facilitates protein synthesis and cell proliferation by modulating the synthesis of cell cycle proteins. EMBO J (2006) 1.28

Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling. Proc Natl Acad Sci U S A (2013) 1.27

Epithelial-to-mesenchymal transition rewires the molecular path to PI3K-dependent proliferation. Cancer Discov (2013) 1.22

Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res (2004) 1.22

Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res (2003) 1.21

Inhibition of Wnt16 in human acute lymphoblastoid leukemia cells containing the t(1;19) translocation induces apoptosis. Oncogene (2005) 1.20

Healing full-thickness cartilage defects using adipose-derived stem cells. Tissue Eng (2007) 1.19

Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell (2002) 1.18

Surgeons' attitudes are associated with reoperation and readmission rates. Clin Orthop Relat Res (2015) 1.17

Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15

What effects have resident work-hour changes had on education, quality of life, and safety? A systematic review. Clin Orthop Relat Res (2015) 1.13

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PLoS One (2012) 1.11

Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res (2005) 1.11

Costello and cardio-facio-cutaneous syndromes: Moving toward clinical trials in RASopathies. Am J Med Genet C Semin Med Genet (2011) 1.10

Killing time for cancer cells. Nat Rev Cancer (2005) 1.08

Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther (2002) 1.07

Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun (2003) 1.07

MDMX inhibits the p300/CBP-mediated acetylation of p53. DNA Cell Biol (2002) 1.06

The RasGAP proteins Ira2 and neurofibromin are negatively regulated by Gpb1 in yeast and ETEA in humans. Mol Cell Biol (2010) 1.03

War wounds: lessons learned from Operation Iraqi Freedom. Plast Reconstr Surg (2008) 1.03

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther (2005) 1.03

Phosphorylation of p16INK4A correlates with Cdk4 association. J Biol Chem (2003) 1.00

Cloning and characterization of the promoter of human Wnt inhibitory factor-1. Biochem Biophys Res Commun (2004) 0.99

Downregulation of Skp2 and p27/Kip1 synergistically induces apoptosis in T98G glioblastoma cells. J Mol Med (Berl) (2004) 0.98

Role for PP2A in ARF signaling to p53. Proc Natl Acad Sci U S A (2004) 0.98

Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther (2006) 0.97

Mad2 inhibits the mitotic kinesin MKlp2. J Cell Biol (2010) 0.97

Patient safety climate among orthopaedic surgery residents. J Bone Joint Surg Am (2011) 0.96

Surgical management of complex proximal humerus fractures-a systematic review of 92 studies including 4500 patients. J Orthop Trauma (2015) 0.96

Adenovirus overrides cellular checkpoints for protein translation. Cell Cycle (2005) 0.94

Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet A (2008) 0.93

Wnt-1 signal as a potential cancer therapeutic target. Drug News Perspect (2006) 0.92

Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options. Hum Mol Genet (2007) 0.91

Critical role for arginine methylation in adenovirus-infected cells. J Virol (2007) 0.90

A prospective analysis of 179 type 2 superior labrum anterior and posterior repairs: outcomes and factors associated with success and failure. Am J Sports Med (2013) 0.90

Replication-selective viruses for cancer therapy. J Mol Med (Berl) (2001) 0.90

What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A (2010) 0.88

Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. Anticancer Res (2003) 0.88

Cancer: survival pathways meet their end. Nature (2004) 0.85

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors. Cancer Res (2014) 0.85

Integrin alphavbeta5 is a primary receptor for adenovirus in CAR-negative cells. Virol J (2010) 0.84

RalGDS comes of age. Cancer Cell (2005) 0.84

The posterolateral portal: optimizing anchor placement and labral repair at the inferior glenoid. Arthrosc Tech (2013) 0.83

Arthroscopic T-capsulotomy for excision of pigmented villonodular synovitis in the hip. Orthopedics (2015) 0.82

MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells. Proc Natl Acad Sci U S A (2013) 0.81

An analysis of capsular area in patients with anterior, posterior, and multidirectional shoulder instability. Am J Sports Med (2008) 0.81

CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A (2014) 0.81

Characterization of interactions between ras family GTPases and their effectors. Methods Enzymol (2006) 0.80

Endoscopic repair of a gluteus medius tear at the musculotendinous junction. Arthrosc Tech (2013) 0.79

Phosphorylation-independent stabilization of p27kip1 by the phosphoinositide 3-kinase pathway in glioblastoma cells. J Biol Chem (2004) 0.78

Subpectoral biceps tenodesis for failed type II SLAP repair. Orthopedics (2013) 0.77

An analysis of the rotator interval in patients with anterior, posterior, and multidirectional shoulder instability. Arthroscopy (2008) 0.77

Future directions: oncolytic viruses. Clin Lung Cancer (2004) 0.76

Killing tumors by keeping ras and PI3' kinase apart. Cancer Cell (2013) 0.75

Topographic analysis of the glenoid and proximal medial tibial articular surfaces: a search for the ideal match for glenoid resurfacing. Am J Sports Med (2013) 0.75

Ras ubiquitination: coupling spatial sorting and signal transmission. Cancer Cell (2006) 0.75

Arthroscopic technique for chondrolabral capsular preservation during labral repair and acetabular osteoplasty. Arthrosc Tech (2013) 0.75

Drug Resistance to EGFR Inhibitors in Lung Cancer. Chemotherapy (2016) 0.75